Ozempic maker Novo Nordisk says it will study drug’s effects on alcohol consumption but isn’t focused on addiction

​ The company plans to start assessing the effects of semaglutide, the active ingredient in Ozempic, and other medicines on alcohol consumption this month in a newly announced clinical trial in alcohol-related liver disease – although cutting drinking isn’t the study’s main goal. Read More Breaking News, Latest News and Videos | CNN